Mentions
Extended reach
Total likes
Video views
AI synopsis
The collective discussions highlight the importance of the trial by emphasizing that apixaban lowers stroke risk but also poses bleeding risks, with tone and language reflecting both curiosity and clinical concern. The use of technical terminology, references to trial data, and debates about management strategies demonstrate high interest and engagement, while the focus on clinical implications suggests a moderate impact on future practice.
Many discussions recognize the study's findings, noting that apixaban reduces stroke risk but with increased bleeding risks, indicating general agreement with the results.
Posts show high interest by referencing detailed trial data, clinical implications, and discussing risk-benefit balance, reflecting strong engagement with the topic.
Numerous posts analyze the trial's results, mention clinical decision-making, and debate treatment strategies, demonstrating deep engagement.
The discussions emphasize significant clinical considerations, such as changing management approaches and balancing risks, indicating moderate but meaningful impact.
Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk of stroke. Whether oral anticoagulation can lower this risk is unclear. Read the full ARTESIA trial Research Summary: https://t.co/5wqdYO3IM6
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM https://t.co/1lDEjxG7gB
Apixaban for stroke prevention in subclinical atrial fibrillation detected by an implantable cardiac monitor: a subgroup analysis of ARTESiA @lucas_yxing @RigsHeart @PHRIresearch https://t.co/aFb3HpicP6
Had a great time presenting the findings of the ARTESiA trial and debating them with @drjohnm in todays Journal Club at @AUHCardio @DCAcademyDK https://t.co/aq7G3Ajl0r
To get situated: check out this powerful
This week’s podcast discusses the KETOCTA study and stroke prevention in patients with device-detected atrial fibrillation. Key findings from two significant trials highlight the effectiveness of direct oral…
Dr Sander van Doorn and Dr Christian Ruff discuss current and future treatment options for stroke prevention in atrial fibrillation patients, focusing on FRAILAF and AZALEA studies exploring anticoagulation therapies…
Providing full prescription coverage after a myocardial infarction increased medication adherence slightly and reduced major vascular events and revascularization rates without raising healthcare costs.
Silent cerebral embolism and antithrombotic strategies in patients with AF and CAD are the focus of this podcast featuring John Mandrola MD. Explore the implications of recent studies on stroke prevention and management…
This week's podcast covers SCAF clues, DOAC reversal trial findings, stroke therapy trials, and changes in observational studies and blood pressure management in stroke care. The discussion provides insights into recent…
This week, John Mandrola MD discusses the implications of left atrial appendage occlusion (LAAO) during cardiac surgery for stroke prevention in atrial fibrillation. Evidence indicates a significant reduction in stroke…
This week’s podcast reviews significant trials including NOAH-AFNET 6 and ARTESiA that highlight the role of direct oral anticoagulants (DOACs) in preventing ischemic stroke among patients with device-detected atrial…
RT @LesterLeung: ARTESIA trial and sub-analysis in people with prior AIS/TIA - Does the amount of #afib matter when deciding on a DOAC vs A…
RT @LesterLeung: ARTESIA trial and sub-analysis in people with prior AIS/TIA - Does the amount of #afib matter when deciding on a DOAC vs A…
ARTESIA trial and sub-analysis in people with prior AIS/TIA - Does the amount of #afib matter when deciding on a DOAC vs ASA to reduce #stroke risk? https://t.co/AE9Qaefri4 https://t.co/oHMq99rduC On balance, Apixaban is better, but the margin is narrower than with perm AF
RT @hrs_journal: Apixaban for stroke prevention in subclinical atrial fibrillation detected by an implantable cardiac monitor: a subgroup a…
RT @hrs_journal: Apixaban for stroke prevention in subclinical atrial fibrillation detected by an implantable cardiac monitor: a subgroup a…
RT @hrs_journal: Apixaban for stroke prevention in subclinical atrial fibrillation detected by an implantable cardiac monitor: a subgroup a…
RT @hrs_journal: Apixaban for stroke prevention in subclinical atrial fibrillation detected by an implantable cardiac monitor: a subgroup a…
RT @hrs_journal: Apixaban for stroke prevention in subclinical atrial fibrillation detected by an implantable cardiac monitor: a subgroup a…
RT @hrs_journal: Apixaban for stroke prevention in subclinical atrial fibrillation detected by an implantable cardiac monitor: a subgroup a…
@hrs_journal @lucas_yxing @RigsHeart @PHRIresearch The use of Apixaban for stroke prevention in subclinical atrial fibrillation is indeed an intriguing area of study. From what this subgroup analysis of ARTESiA suggests, it seems that implantable cardiac monitors could play a key role in identifying patients who might benefit
RT @hrs_journal: Apixaban for stroke prevention in subclinical atrial fibrillation detected by an implantable cardiac monitor: a subgroup a…
RT @hrs_journal: Apixaban for stroke prevention in subclinical atrial fibrillation detected by an implantable cardiac monitor: a subgroup a…
RT @hrs_journal: Apixaban for stroke prevention in subclinical atrial fibrillation detected by an implantable cardiac monitor: a subgroup a…
Apixaban for stroke prevention in subclinical atrial fibrillation detected by an implantable cardiac monitor: a subgroup analysis of ARTESiA @lucas_yxing @RigsHeart @PHRIresearch https://t.co/aFb3HpicP6
#HeartMonth facts about the role of smart devices. Learn more about the Atresia trial https://t.co/jYEsNxwxrE https://t.co/V7LSoqxjeH
@Mel_Gunawardene @EHRAPresident @arbelo_e NOAH-AF-NET https://t.co/1VC5pjGT0k ARTESiA https://t.co/mRmdJWh0qV #EHRAchat https://t.co/SWqFZaCoqH
@towa2405 6分程度でも塞栓症のリスクは上がると考えられています。ただ、DOACを導入してみたらどうかということについてはNOAH-AFNET6、ARTESIAという試験でbenefitを示せませんでした。CHADS 0点の臨床的に診断されたAFにDOACを導入するか、に似ています。 https://t.co/iMHDAd9RaT https://t.co/P9dVPGWx0C
https://t.co/yVqxEhQoCJ
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation DOI: 10.1056/NEJMoa2310234 https://t.co/mgIh7tNz5H
RT @SeguraCardio:
RT @PBasiukiewicz: @InPartibusInfid Była taka koncepcja, żeby leczyć przeciwzakrsepowo atriopatię u osób z ESUS. https://t.co/hOvT0VidiP…
@InPartibusInfid Była taka koncepcja, żeby leczyć przeciwzakrsepowo atriopatię u osób z ESUS. https://t.co/hOvT0VidiP Była też koncepcja żeby leczyć subkliniczne AF. https://t.co/Gk5B2OX5ah OBIE upadły.
La terapia anticoagulante con apixaban ha ridotto il rischio di stroke, con una riduzione del 49% del rischio di ictus con disabilità residua o fatale, al prezzo di un aumento del rischio di sanguinamento non fatale https://t.co/wudE6plLlU
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation Le implicazioni cliniche delle informazioni provenienti dai dispositivi cardiaci #FibrillazioneAtriale #Ictus #aggiornatisSIMI #NEJM https://t.co/6CcvOa3a02
RT @RevistaMFSamfyc: Apixaban para la prevención del ictus en la fibrilación auricular subclínica https://t.co/2VZGXebXbg PMID 37952132
We enjoyed the half-day academic lecture titled “Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA)” presented by Dr. Aljoharah Alqub, R1 Pharmacy Resident https://t.co/5FnEtrVvHC
https://t.co/Dm2Q9Uy68j
RT @HenrikLBjerre: Had a great time presenting the findings of the ARTESiA trial and debating them with @drjohnm in todays Journal Club at…
RT @HenrikLBjerre: Had a great time presenting the findings of the ARTESiA trial and debating them with @drjohnm in todays Journal Club at…
RT @HenrikLBjerre: Had a great time presenting the findings of the ARTESiA trial and debating them with @drjohnm in todays Journal Club at…
Had a great time presenting the findings of the ARTESiA trial and debating them with @drjohnm in todays Journal Club at @AUHCardio @DCAcademyDK https://t.co/aq7G3Ajl0r
@QRSfans @ecgandrhythmRoe @ecgrhythms https://t.co/m0arXZpfNx
RT @quinonezmd: En pacientes con fibrilación auricular subclínica (detectada por marcapasos o ICD) y CHA₂DS₂-VASc 3 puntos. Apixaban ⬇️ e…
RT @2minmed: #VisualAbstract: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation https://t.co/zeN9RV6ipz #StudyGraphics #ant…
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation: Apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding. https://t.co/d1vRjMSysA
RT @ZHeart11768530: Balancing the benefits and risks of anticoagulation in patients with subclinical atrial fibrillation Comment on ARTESI…
Quando anche la FA subclinica può aumentare il rischio trombotico la soluzione c è... https://t.co/ktH5EPCi7Y
RT @quinonezmd: En pacientes con fibrilación auricular subclínica (detectada por marcapasos o ICD) y CHA₂DS₂-VASc 3 puntos. Apixaban ⬇️ e…
RT @quinonezmd: En pacientes con fibrilación auricular subclínica (detectada por marcapasos o ICD) y CHA₂DS₂-VASc 3 puntos. Apixaban ⬇️ e…
En pacientes con fibrilación auricular subclínica (detectada por marcapasos o ICD) y CHA₂DS₂-VASc 3 puntos. Apixaban ⬇️ el riesgo de infarto cerebral y embolismo sistémico VS aspirina. Y ⬆️ el riesgo de sangrado mayor. https://t.co/TDzgfJFag8 https://t.co/6PpDi2FZRt
@drjohnm @venkmurthy Until ARTESIA, yours was my take as well. But, how do you reconcile these results? Apixaban associated with increased major bleeding by factor of 1.8 compared to Aspirin. https://t.co/jWETM27Qnk https://t.co/V77jAZouzj
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @medibook3: 先月のNEJMより6分〜24時間以内の持続で検出されたsubclinical Afに対するapixabanの予防効果のRCT。 脳梗塞や塞栓イベントは減るけれど、出血は増えることでrisk-benefit balanceが未だ難しいところ。検出に…
RT @medibook3: 先月のNEJMより6分〜24時間以内の持続で検出されたsubclinical Afに対するapixabanの予防効果のRCT。 脳梗塞や塞栓イベントは減るけれど、出血は増えることでrisk-benefit balanceが未だ難しいところ。検出に…
先月のNEJMより6分〜24時間以内の持続で検出されたsubclinical Afに対するapixabanの予防効果のRCT。 脳梗塞や塞栓イベントは減るけれど、出血は増えることでrisk-benefit balanceが未だ難しいところ。検出にかかるコスト負担を踏まえると中々積極的な気持ちになりにくい。 https://t.co/Xv3eUjwB2G
無症候性心房細動にエリキュースはアスピリンより脳卒中・全身塞栓症を減らすが出血は増やす。脳梗塞を年間0.5%程度(0.57vs1.05)抑制し脳卒中になっても転帰いいのが3分の２(vs半分)。一方で出血はほとんどが非致死的な消化管出血0.89%/y。年間1％の脳梗塞に対してどう考えるかhttps://t.co/ttX9urGeke
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation #HeartWellness #HeartAttack #HeartAware #HeartAwareness [Video] The ARTESIA trial demonstrates that Apixaban effectively reduces the risk of stroke or systemic embolism in patients with… https://t.co/nX78FPfLUk
@FGProcopio @CONAREC_ORG @SIAC_cardio @ComunidadFAC @clinicasac Si sumamos a tu
RT @drsapg: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM https://t.co/N4qfKGJymi Justifica mandar a tomar antic…
2 min cardiology（臨床論文、担当：後岡広太郎） Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation J S Healey et al. N Engl J Med 2024; 390: 107-17 https://t.co/0XKk1MPv26 無症候性心房細動は持続時間が短く無症状ですが脳梗塞のリスクが 2.5 倍と報告されています。 →
#Apixaban for #Stroke #Prevention in #Subclinical #Atrial #Fibrillation | SOMEONE SOMEWHERE (https://t.co/JnxfQijLjy)
RT @CardioNerdsJC: To get situated: check out this powerful
Apixaban para la prevención del ictus en la fibrilación auricular subclínica https://t.co/2VZGXebXbg PMID 37952132
RT @CardioNerdsJC: To get situated: check out this powerful
RT @CardioNerdsJC: To get situated: check out this powerful
RT @CardioNerdsJC: To get situated: check out this powerful
RT @CardioNerdsJC: To get situated: check out this powerful
To get situated: check out this powerful
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
Among patients with subclinical atrial fibrillation, apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding. https://t.co/sPKeOafBid
RT @drtintin99: 1/ Today's #MorningPaper looks at this randomised double-blind trial of apixaban Vs aspirin for subclinical #AF in preventi…
RT @BITNavarra: Apixaban para la prevención del accidente cerebrovascular en fibrilación auricular @salud_na https://t.co/YZBpOvA4dn
RT @SeguraCardio:
RT @BITNavarra: Apixaban para la prevención del accidente cerebrovascular en fibrilación auricular @salud_na https://t.co/YZBpOvA4dn
RT @BITNavarra: Apixaban para la prevención del accidente cerebrovascular en fibrilación auricular @salud_na https://t.co/YZBpOvA4dn
RT @BITNavarra: Apixaban para la prevención del accidente cerebrovascular en fibrilación auricular @salud_na https://t.co/YZBpOvA4dn
Apixaban para la prevención del accidente cerebrovascular en fibrilación auricular @salud_na https://t.co/YZBpOvA4dn
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM https://t.co/DlQ2lGpzaY
Apixaban Vs Aspirina para prevención de ictus en pacientes con fibrilación auricular subclínica (duración menor de 24 horas y sin síntomas):
Apixaban para la prevención del accidente cerebrovascular en la fibrilación auricular subclínica: En estos pacientes, apixaban obtuvo un menor riesgo de accidente cerebrovascular o embolia sistémica que la aspirina, pero un mayor riesgo de hemorragia grave https://t.co/MkNdOhPeH6
In patients with subclinical #AF, apixaban led to a lower risk of stroke or systemic embolism but more major bleeding compared to aspirin. @NEJM https://t.co/20mH1tHg7b
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @drtintin99: 1/ Today's #MorningPaper looks at this randomised double-blind trial of apixaban Vs aspirin for subclinical #AF in preventi…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
RT @NEJM: Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk o…
Subclinical atrial fibrillation is common among persons with implanted cardiac devices and is associated with an increased risk of stroke. Whether oral anticoagulation can lower this risk is unclear. Read the full ARTESIA trial Research Summary: https://t.co/5wqdYO3IM6
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @drtintin99: 1/ Today's #MorningPaper looks at this randomised double-blind trial of apixaban Vs aspirin for subclinical #AF in preventi…
1/ Today's #MorningPaper looks at this randomised double-blind trial of apixaban Vs aspirin for subclinical #AF in preventing #Stroke based on 4012 patients with avg CHA2DC2-VASc score of 3.9. @StrokeImperial @e1v1m1 @drjkwan @cerysamorgan1 @DrGeorgePeck https://t.co/MIicQmQnIc
RT @mitcharj: Apixaban for stroke prevention in subclinical atrial fibrillation https://t.co/7J0InyajQI #AFib #Prevention #artesia #Stroke…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
https://t.co/a1DG2rrBQb
RT @SeguraCardio:
RT @vic_pallares: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | @NEJM https://t.co/QyWGZf4ry3
RT @mitcharj: Apixaban for stroke prevention in subclinical atrial fibrillation https://t.co/7J0InyajQI #AFib #Prevention #artesia #Stroke…
Apixaban for stroke prevention in subclinical atrial fibrillation https://t.co/7J0InyajQI #AFib #Prevention #artesia #Stroke via @NEJM https://t.co/sGNfbZHuvo
RT @SEMERGENap:
RT @SeguraCardio:
RT @stephanamayer: Why bother anticoagulating with apixaban for subclinical paroxysmal A Fib when the absolute risk reduction for stroke is…
RT @SEMERGENap:
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM https://t.co/S1TMmcloIQ
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM https://t.co/lfgvIY0Oji
RT @stephanamayer: Why bother anticoagulating with apixaban for subclinical paroxysmal A Fib when the absolute risk reduction for stroke is…
RT @SEMERGENap:
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
#clinicalquestion Does ATRESIA change our management, or we remain mainly "pt centered, risk/benefit" for subclinical low burden AF, whilst awaiting more data? @NEJM @drjohnm @DrJMarine #EPpeeps https://t.co/B4c21UZpcU https://t.co/UtK0CNdq0W
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @SeguraCardio:
神経集中治療関連文献
RT @namorrismd: For me, #ARTESIA begs for shared decision making in subclinical AF. Lower risk of stroke and less severe stroke with apixa…
RT @SeguraCardio:
RT @stephanamayer: Why bother anticoagulating with apixaban for subclinical paroxysmal A Fib when the absolute risk reduction for stroke is…
RT @rincondesisifo: (NEJM) Seguridad y eficacia del apixabán vs ácido acetilsalicílico en la prevención de ACV en pac con una FA subclínica…
RT @stephanamayer: Why bother anticoagulating with apixaban for subclinical paroxysmal A Fib when the absolute risk reduction for stroke is…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @SeguraCardio:
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @SeguraCardio:
RT @SeguraCardio:
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM Among patients with subclinical atrial fibrillation, apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding https://t.co/BnA4FbxPBz
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding. https://t.co/SICuHiMfBq
RT @stephanamayer: Why bother anticoagulating with apixaban for subclinical paroxysmal A Fib when the absolute risk reduction for stroke is…
RT @stephanamayer: Why bother anticoagulating with apixaban for subclinical paroxysmal A Fib when the absolute risk reduction for stroke is…
RT @SeguraCardio:
RT @SeguraCardio:
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @SeguraCardio:
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @stephanamayer: Why bother anticoagulating with apixaban for subclinical paroxysmal A Fib when the absolute risk reduction for stroke is…
RT @stephanamayer: Why bother anticoagulating with apixaban for subclinical paroxysmal A Fib when the absolute risk reduction for stroke is…
RT @stephanamayer: Why bother anticoagulating with apixaban for subclinical paroxysmal A Fib when the absolute risk reduction for stroke is…
RT @stephanamayer: Why bother anticoagulating with apixaban for subclinical paroxysmal A Fib when the absolute risk reduction for stroke is…
RT @stephanamayer: Why bother anticoagulating with apixaban for subclinical paroxysmal A Fib when the absolute risk reduction for stroke is…
RT @SeguraCardio:
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @SeguraCardio:
RT @SeguraCardio:
RT @stephanamayer: Why bother anticoagulating with apixaban for subclinical paroxysmal A Fib when the absolute risk reduction for stroke is…
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM https://t.co/zG3NrRcIdN
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @stephanamayer: Why bother anticoagulating with apixaban for subclinical paroxysmal A Fib when the absolute risk reduction for stroke is…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @stephanamayer: Why bother anticoagulating with apixaban for subclinical paroxysmal A Fib when the absolute risk reduction for stroke is…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @NEJM: Original Article: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation (ARTESIA trial) https://t.co/5wqdYO3aWy Edi…
RT @ZHeart11768530: Balancing the benefits and risks of anticoagulation in patients with subclinical atrial fibrillation Comment on ARTESI…
RT @ZHeart11768530: Balancing the benefits and risks of anticoagulation in patients with subclinical atrial fibrillation Comment on ARTESI…
RT @ZHeart11768530: Balancing the benefits and risks of anticoagulation in patients with subclinical atrial fibrillation Comment on ARTESI…
Balancing the benefits and risks of anticoagulation in patients with subclinical atrial fibrillation Comment on ARTESIA trial published @NEJM
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM https://t.co/GXG6RkIo1i
RT @pinacol: 【RCT】6分から24時間持続する無症候性心房細動患者へのアピキサバン投与は、アスピリンの投与と比較して、脳卒中または全身性塞栓症のリスクを低下させた一方、大出血のリスクを増加させた。 #ペ読 https://t.co/EdebKAtj7K
RT @naitostrokereha: Apxaban(エリキュース)とアスピリンでAF背景の心原性脳塞栓症と出血の有害事象を比較、脳塞栓症減少も出血事例増加と
Apxaban(エリキュース)とアスピリンでAF背景の心原性脳塞栓症と出血の有害事象を比較、脳塞栓症減少も出血事例増加と
【RCT】6分から24時間持続する無症候性心房細動患者へのアピキサバン投与は、アスピリンの投与と比較して、脳卒中または全身性塞栓症のリスクを低下させた一方、大出血のリスクを増加させた。 #ペ読 https://t.co/EdebKAtj7K
Trending on PubMed: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. https://t.co/hBn3kVWcFc
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation - PubMed #ncbi https://t.co/Q8bNrEIrmR
RT @theindianheart: Open access #FOAMed https://t.co/KcoCzajHTQ
Open access #FOAMed https://t.co/KcoCzajHTQ
RT @AshuPJadhav: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM https://t.co/1lDEjxG7gB
RT @AshuPJadhav: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM https://t.co/1lDEjxG7gB
RT @EARL_med_tw:
RT @AshuPJadhav: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM https://t.co/1lDEjxG7gB
RT @AshuPJadhav: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM https://t.co/1lDEjxG7gB
Yaygın olarak kullanılan kan sulandırıcı apiksaban, yalnızca kalp pili veya implante edilmiş başka bir elektronik kalp cihazı tarafından tespit edilebilen bir atriyal fibrilasyon formuna sahip yüksek riskli hastalarda felçleri önemli ölçüde azaltmış. https://t.co/hN1rizHvtj
RT @AshuPJadhav: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM https://t.co/1lDEjxG7gB
RT @AshuPJadhav: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM https://t.co/1lDEjxG7gB
RT @AshuPJadhav: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM https://t.co/1lDEjxG7gB
RT @AshuPJadhav: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM https://t.co/1lDEjxG7gB
RT @AshuPJadhav: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM https://t.co/1lDEjxG7gB
Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | NEJM https://t.co/1lDEjxG7gB
HM
BT
LM